{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:13:44Z","timestamp":1772165624498,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["Z-2021-46-2101"],"award-info":[{"award-number":["Z-2021-46-2101"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In Chinese healthcare settings, drug selection decisions are predominantly influenced by the Pharmacy &amp; Therapeutics Committee (PTC). This study evaluates two recently introduced potassium-competitive acid blockers, vonoprazan (VPZ) and tegoprazan (TPZ), utilizing the Evidence and Value: Impact on DEcisionMaking (EVIDEM) framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study employed the 10th edition of EVIDEM, which includes a core model with five domains and 13 criteria. Two independent expert panels were involved: the PTC expert panel, tasked with assigning weights using a 5-point scale, defining scoring indicators, examining the evidence matrix, scoring, and decision-making; and the evidence matrix expert panel, responsible for conducting a systematic literature review, creating the evidence matrix, and evaluating the value contributions of VPZ and TPZ.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis estimated the value contributions of VPZ and TPZ to be 0.59 and 0.54, respectively. The domain of \u2018economic consequences of intervention\u2019 showed the most significant variation in value contribution between the two drugs, followed by \u2018comparative outcomes of intervention\u2019 and \u2018type of benefit of intervention\u2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Employing the EVIDEM framework, VPZ\u2019s value contribution was found to be marginally superior to that of TPZ. The EVIDEM framework demonstrates potential for broader application in Chinese medical institutions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-024-03297-6","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T04:03:05Z","timestamp":1718856185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating vonoprazan and tegoprazan for gastroesophageal reflux disease treatment in Chinese Healthcare: an EVIDEM framework analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Chaojun","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haotian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingnan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanjun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"issue":"1","key":"3297_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1186\/s12913-021-06827-0","volume":"21","author":"Y BAO","year":"2021","unstructured":"BAO Y, GAO B, MENG M, et al. Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors. BMC Health Serv Res. 2021;21(1):807.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"3297_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1468-0009.2008.00519.x","volume":"86","author":"LA JEWELL C J, BERO","year":"2008","unstructured":"JEWELL C J, BERO LA. Developing good taste in evidence: facilitators of and hindrances to evidence-informed health policymaking in state government. Milbank Q. 2008;86(2):177\u2013208.","journal-title":"Milbank Q"},{"key":"3297_CR3","doi-asserted-by":"crossref","unstructured":"EDDY D. Reflections on science, judgment, and value in evidence-based decision making: a conversation with David. Eddy Sean R Tunis Health Aff (Millwood), 2007,26(4): w500\u201315.","DOI":"10.1377\/hlthaff.26.4.w500"},{"key":"3297_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/1472-6963-8-270","volume":"8","author":"M GOETGHEBEUR M M, WAGNER","year":"2008","unstructured":"GOETGHEBEUR M M, WAGNER M. Evidence and value: impact on DEcisionMaking\u2013the EVIDEM framework and potential applications. BMC Health Serv Res. 2008;8:270.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"3297_CR5","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1177\/0272989X11416870","volume":"32","author":"M GOETGHEBEUR M M, WAGNER","year":"2012","unstructured":"GOETGHEBEUR M M, WAGNER M, KHOURY H, et al. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal. Med Decis Mak. 2012;32(2):376\u201388.","journal-title":"Med Decis Mak"},{"issue":"Suppl 1","key":"3297_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12962-018-0116-9","volume":"16","author":"MS GOETGHEBEUR M M, CELLIER","year":"2018","unstructured":"GOETGHEBEUR M M, CELLIER MS. Can reflective multicriteria be the new paradigm for healthcare decision-making? The EVIDEM journey. Cost Eff Resour Alloc. 2018;16(Suppl 1):54.","journal-title":"Cost Eff Resour Alloc"},{"key":"3297_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1478-7547-9-16","volume":"9","author":"S Youngkong","year":"2011","unstructured":"Youngkong S, Tromp N, Chitama D. Erratum to: the EVIDEM framework and its usefulness for priority setting across a broad range of health interventions. Cost Eff Resour Alloc. 2011;9:16. https:\/\/doi.org\/10.1186\/1478-7547-9-16","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"3297_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41572-021-00287-w","volume":"7","author":"R FASS","year":"2021","unstructured":"FASS R, BOECKXSTAENS G E, EL-SERAG H, et al. Gastro-oesophageal reflux disease. Nat Rev Dis Primers. 2021;7(1):55.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"3297_CR9","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cgh.2022.01.025","volume":"20","author":"R YADLAPATI","year":"2022","unstructured":"YADLAPATI R, GYAWALI C P, PANDOLFINO JE. AGA clinical practice update on the Personalized Approach to the evaluation and management of GERD: Expert Review. Clin Gastroenterol Hepatol. 2022;20(5):984\u201394.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"3297_CR10","doi-asserted-by":"publisher","first-page":"e14075","DOI":"10.1111\/nmo.14075","volume":"33","author":"F ZERBIB","year":"2021","unstructured":"ZERBIB F, BREDENOORD A J, FASS R, et al. ESNM\/ANMS consensus paper: diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol Motil. 2021;33(4):e14075.","journal-title":"Neurogastroenterol Motil"},{"issue":"3","key":"3297_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/87551225231166531","volume":"39","author":"PHILLIPSB ST O E","year":"2023","unstructured":"ST O E PHILLIPSB, Vonoprazan. A New Potassium-competitive acid blocker. J Pharm Technol. 2023;39(3):139\u201346.","journal-title":"J Pharm Technol"},{"key":"3297_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6963-11-329","volume":"11","author":"M Tony","year":"2011","unstructured":"Tony M, Wagner M, Khoury H, et al. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada. BMC Health Serv Res. 2011;11:1\u20133.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"3297_CR13","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/14737167.2022.2063842","volume":"22","author":"N Zozaya","year":"2022","unstructured":"Zozaya N, Abdalla F, Alfonso Zamora S, et al. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert Rev PharmacoEcon Outcomes Res. 2022;22(6):941\u201353.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"key":"3297_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40259-018-0284-3","volume":"32","author":"N Zozaya","year":"2018","unstructured":"Zozaya N, Mart\u00ednez-Galdeano L, Alcal\u00e1 B, et al. Determining the value of two biologic drugs for chronic inflammatory skin diseases: results of a multi-criteria decision analysis. BioDrugs. 2018;32:281\u201391.","journal-title":"BioDrugs"},{"issue":"2","key":"3297_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.dld.2008.06.014","volume":"41","author":"R WANG","year":"2009","unstructured":"WANG R, YAN X, MA X Q, et al. Burden of gastroesophageal reflux disease in Shanghai, China. Dig Liver Dis. 2009;41(2):110\u20135.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"3297_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S2468-1253(19)30408-X","volume":"5","author":"S DIRAC M A, SAFIRI","year":"2020","unstructured":"DIRAC M A, SAFIRI S. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(6):561\u201381.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"3297_CR17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/apt.13331","volume":"42","author":"K ASHIDA","year":"2015","unstructured":"ASHIDA K, SAKURAI Y, NISHIMURA A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42(6):685\u201395.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3297_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/apt.13461","volume":"43","author":"K ASHIDA","year":"2016","unstructured":"ASHIDA K, SAKURAI Y, HORI T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240\u201351.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3297_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1136\/gutjnl-2019-318365","volume":"69","author":"Y XIAO","year":"2020","unstructured":"XIAO Y, ZHANG S, DAI N, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020;69(2):224\u201330.","journal-title":"Gut"},{"issue":"7","key":"3297_CR20","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/apt.15185","volume":"49","author":"GH LEE K J, SON B K, KIM","year":"2019","unstructured":"LEE K J, SON B K, KIM GH, et al. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49(7):864\u201372.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"3297_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/apt.15641","volume":"51","author":"T TAKEUCHI","year":"2020","unstructured":"TAKEUCHI T, FURUTA T, FUJIWARA Y, et al. Randomised trial of acid inhibition by Vonoprazan 10\/20\u00a0mg once daily vs rabeprazole 10\/20\u00a0mg twice daily in healthy Japanese volunteers (SAMURAI pH study). Aliment Pharmacol Ther. 2020;51(5):534\u201343.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"3297_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y SAKURAI","year":"2015","unstructured":"SAKURAI Y, MORI Y, OKAMOTO H, et al. Acid-inhibitory effects of vonoprazan 20\u00a0mg compared with esomeprazole 20\u00a0mg or rabeprazole 10\u00a0mg in healthy adult male subjects\u2013a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719\u201330.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"3297_CR23","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.14309\/ajg.0000000000001735","volume":"117","author":"L LAINE","year":"2022","unstructured":"LAINE L, SHARMA P, MULFORD D J, et al. Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker Vonoprazan and the Proton pump inhibitor lansoprazole in US subjects. Am J Gastroenterol. 2022;117(7):1158\u201361.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"3297_CR24","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1111\/bcp.15268","volume":"88","author":"E YANG","year":"2022","unstructured":"YANG E, KIM S, KIM B, et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J Clin Pharmacol. 2022;88(7):3288\u201396.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3297_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5009\/gnl220050","volume":"17","author":"S HAN","year":"2023","unstructured":"HAN S, CHOI H Y, KIM Y H, et al. Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole regarding nocturnal acid breakthrough: a randomized crossover study. Gut Liver. 2023;17(1):92\u20139.","journal-title":"Gut Liver"},{"issue":"6","key":"3297_CR26","first-page":"294","volume":"115","author":"H GONG","year":"2023","unstructured":"GONG H, HAN D, LIU S, et al. Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis. Rev Esp Enferm Dig. 2023;115(6):294\u2013300.","journal-title":"Rev Esp Enferm Dig"},{"issue":"5","key":"3297_CR27","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/apt.15865","volume":"52","author":"CHO Y K","year":"2020","unstructured":"CHO Y K, CHOI M G, CHOI S C, et al. Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Ther. 2020;52(5):789\u201397.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3297_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5056\/jnm22104","volume":"29","author":"JS KIM","year":"2023","unstructured":"KIM JS, SEO S I, KANG S H, et al. Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: a Multicenter double-blind Randomized Controlled Trial. J Neurogastroenterol Motil. 2023;29(1):58\u201364.","journal-title":"J Neurogastroenterol Motil"},{"issue":"1","key":"3297_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/apt.17255","volume":"57","author":"HS CHO Y K, KIM J H, KIM","year":"2023","unstructured":"CHO Y K, KIM J H, KIM HS, et al. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Aliment Pharmacol Ther. 2023;57(1):72\u201380.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3297_CR30","doi-asserted-by":"publisher","first-page":"e14468","DOI":"10.1111\/nmo.14468","volume":"35","author":"J TACK","year":"2023","unstructured":"TACK J, VLADIMIROV B, HORNY I, et al. Randomized clinical trial: a double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40\u00a0mg versus esomeprazole 40\u00a0mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor. Neurogastroenterol Motil. 2023;35(1):e14468.","journal-title":"Neurogastroenterol Motil"},{"issue":"2","key":"3297_CR31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/apt.15062","volume":"49","author":"T OSHIMA","year":"2019","unstructured":"OSHIMA T, ARAI E, TAKI M, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49(2):140\u20136.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"3297_CR32","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/apt.16477","volume":"54","author":"SH KIM","year":"2021","unstructured":"KIM SH, CHO K B CHUNHJ, et al. Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment Pharmacol Ther. 2021;54(4):402\u201311.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"3297_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10388-019-00676-x","volume":"16","author":"T TANABE","year":"2019","unstructured":"TANABE T, HOSHINO S, KAWAMI N, et al. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Esophagus. 2019;16(4):377\u201381.","journal-title":"Esophagus"},{"issue":"10","key":"3297_CR34","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/apt.13588","volume":"43","author":"T KAGAMI","year":"2016","unstructured":"KAGAMI T, SAHARA S, ICHIKAWA H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43(10):1048\u201359.","journal-title":"Aliment Pharmacol Ther"},{"key":"3297_CR35","first-page":"1098305599","volume":"15","author":"M ZHANG","year":"2022","unstructured":"ZHANG M, XIAO Y, CHEN M. The role of vonoprazan in patients with erosive esophagitis. Th Adv Gastroenterol. 2022;15:1098305599.","journal-title":"Th Adv Gastroenterol"},{"issue":"2","key":"3297_CR36","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000456072","volume":"95","author":"S HOSHINO","year":"2017","unstructured":"HOSHINO S, KAWAMI N, TAKENOUCHI N, et al. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis. Digestion. 2017;95(2):156\u201361.","journal-title":"Digestion"},{"key":"3297_CR37","doi-asserted-by":"crossref","unstructured":"Zhuang Q, Chen S, Zhou X et al. Comparative efficacy of P-CAB vs Proton Pump inhibitors for Grade C\/D Esophagitis: a systematic review and network Meta-analysis. Am J Gastroenterol Published Online March 22, 2024.","DOI":"10.14309\/ajg.0000000000002714"},{"issue":"8","key":"3297_CR38","doi-asserted-by":"publisher","first-page":"480","DOI":"10.21037\/atm-22-1722","volume":"10","author":"Z WANG","year":"2022","unstructured":"WANG Z, SUN R, SHENG Y, et al. Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China. Ann Transl Med. 2022;10(8):480.","journal-title":"Ann Transl Med"},{"issue":"4","key":"3297_CR39","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00535-022-01861-z","volume":"57","author":"K IWAKIRI","year":"2022","unstructured":"IWAKIRI K, FUJIWARA Y, MANABE N, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022;57(4):267\u201385.","journal-title":"J Gastroenterol"},{"issue":"4","key":"3297_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.5056\/jnm21077","volume":"27","author":"JUNG H K","year":"2021","unstructured":"JUNG H K, TAE C H, SONG K H, et al. 2020 Seoul Consensus on the diagnosis and management of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2021;27(4):453\u201381.","journal-title":"J Neurogastroenterol Motil"},{"issue":"11\u201312","key":"3297_CR41","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/apt.13414","volume":"42","author":"MARCUSEA SCOTT D R, MUNSON K B","year":"2015","unstructured":"SCOTT D R, MUNSON K B MARCUSEA, et al. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+-ATPase. Aliment Pharmacol Ther. 2015;42(11\u201312):1315\u201326.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"3297_CR42","first-page":"11","volume":"6","author":"R TUTUIAN","year":"2004","unstructured":"TUTUIAN R. CASTELL D O. nocturnal acid breakthrough - approach to management. MedGenMed. 2004;6(4):11.","journal-title":"MedGenMed"},{"issue":"7","key":"3297_CR43","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1590-8658(02)80102-5","volume":"34","author":"KENNERLEYP MCCOLL K E","year":"2002","unstructured":"MCCOLL K E KENNERLEYP. Proton pump inhibitors\u2013differences emerge in hepatic metabolism. Dig Liver Dis. 2002;34(7):461\u20137.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"3297_CR44","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/cpdd.1009","volume":"11","author":"DJ MULFORD","year":"2022","unstructured":"MULFORD DJ, LEIFKE E, HIBBERD M, et al. The Effect of Food on the pharmacokinetics of the potassium-competitive acid blocker Vonoprazan. Clin Pharmacol Drug Dev. 2022;11(2):278\u201384.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"3297_CR45","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/cts.12958","volume":"14","author":"J YOON D Y, SUNWOO","year":"2021","unstructured":"YOON D Y, SUNWOO J, SHIN N, et al. Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers. Clin Transl Sci. 2021;14(3):934\u201341.","journal-title":"Clin Transl Sci"},{"issue":"11","key":"3297_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/15265161.2019.1665402","volume":"19","author":"T BEAUCHAMP","year":"2019","unstructured":"BEAUCHAMP T. Principles of Biomedical Ethics: marking its Fortieth Anniversary. Am J Bioeth. 2019;19(11):9\u201312.","journal-title":"Am J Bioeth"},{"issue":"4","key":"3297_CR47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G GUYATT","year":"2011","unstructured":"GUYATT G, OXMAN A D, AKL E A, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394.","journal-title":"J Clin Epidemiol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03297-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03297-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03297-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T05:03:10Z","timestamp":1718859790000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03297-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3297"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03297-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3930251\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Hebei General Hospital Ethics Committee. Because of the analysis used anonymous clinical data, written informed consent from subjects was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}